loading

About Author

At Labstica, we are dedicated to innovation, collaboration, and seamless growth.

Contact Info

Dr Hamat IAT
Dr. Hamat, Principal Investigator

Dr. Hamat serves as the Principal Investigator at Integrity Advanced Therapeutics (IAT), leading all clinical research initiatives focused on gastroenterology and liver diseases.
With extensive clinical expertise and a strong background in both patient care and research, Dr. Hamat oversees the scientific integrity, patient safety, and regulatory compliance of all trials conducted at the site.

A distinguished gastroenterologist, Dr. Hamat brings a passion for innovation and a deep commitment to translating research into real-world treatments that enhance patient outcomes.
Under his leadership, IAT conducts Phase I–IV trials across a wide range of gastrointestinal and hepatic conditions, including Inflammatory Bowel Disease (IBD), functional GI disorders, NAFLD, and liver fibrosis.

Dr. Hamat is known for his patient-first philosophy, scientific rigor, and collaborative spirit, making him an integral leader in advancing new therapies for complex digestive and liver diseases.

Skills & Qualifications
  • Inflammatory Bowel Disease (Crohn’s Disease, Ulcerative Colitis)
  • Gastroesophageal Reflux Disease (GERD)
  • Functional Gastrointestinal Disorders (Gastroparesis, Dyspepsia)
  • Liver Disease Research (NAFLD, Hepatitis, Cirrhosis)
  • Clinical Trial Protocol Development and Execution
  • Regulatory Compliance (FDA, ICH-GCP)
Professional Experience
  • 15+ years of experience in gastroenterology clinical practice and research
  • Principal Investigator for multiple Phase II–IV gastrointestinal and hepatology clinical trials
  • Experienced in managing multi-site studies, ensuring both scientific quality and patient safety
  • Dedicated to integrating clinical care with research innovation
Research Leadership
  • Leads study feasibility, protocol evaluation, and regulatory submissions
  • Directs patient enrollment strategies, ensuring diverse and representative study populations
  • Collaborates with pharmaceutical sponsors and CROs to bring novel treatments to market